HGF is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

HGF is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

HGF is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

HGF is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

HGF is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains HGF status and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

HGF is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

HGF is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains HGF status and glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

HGF is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

HGF is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

HGF is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains HGF status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

HGF is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains HGF status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

HGF is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

HGF is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

HGF is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

HGF is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

HGF is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

HGF is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HGF status and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [4].